This article shares the insights of a study presented at Digestive Disease Week in 2019. This retrospective chart review is “the largest case study to date to examine oral vancomycin in patients with UC-PSC.” This research showed that “oral vancomycin safely induced and maintained remission of ulcerative colitis among a subset of patients with ulcerative […]
Cancer Risk in Primary Sclerosing Cholangitis: Epidemiology, Prevention, and Surveillance Strategies
This research paper provides a helpful overview of the various types of cancers PSC patients are at risk of developing, as well as ways to screen for cancer. The cancers discussed in this paper are cholangiocarcinoma, gallbladder cancer, hepatocellular carcinoma, pancreatic cancer, and colorectal cancer. Screening methods covered in this paper include MRIs/MRCPs, CA 19-9 […]
Ulcerative Colitis Pipeline Insight 2024 | FDA Approvals, Clinical Trials, and Therapies
This press release shares data gathered by DelveInsight—a healthcare-focused market research and consulting firm. This article is super exciting and hopeful, as it shows some promising IBD therapies in the pipeline, from pills to subcutaneous injections to IV biologics. One of the therapies listed under “promising ulcerative colitis therapies” is oral vancomycin! I believe there’s […]
Oral Vancomycin Induced and Maintained Clinical and Endoscopic Remission in Ulcerative Colitis and Primary Sclerosing Cholangitis Post-liver Transplantation
This case study followed a 34-year-old man with PSC and ulcerative colitis who did not respond to multiple advanced therapies, and who had a liver transplant. Before his liver transplant, he tried mesalamine and Remicade without achieving remission. After his liver transplant, his UC flared and he tried Remicade, Entyvio, Humira, Xeljanz, and Stelara. However, […]
Oral vancomycin is associated with improved inflammatory bowel disease clinical outcomes in primary sclerosing cholangitis-associated inflammatory bowel disease (PSC-IBD): A matched analysis from the Paediatric PSC Consortium
In this retrospective study, the Paediatric PSC Consortium compared the health of patients with PSC and IBD who had taken oral vancomycin (OV) to PSC-IBD patients who had not taken OV. Out of 113 patients with PSC-IBD, 70 were treated with OV, and they had a better chance of their IBD going into remission compared […]
Complete Biochemical Remission With Oral Vancomycin in a Patient With Primary Sclerosing Cholangitis and High Serum Immunoglobulin G4 Levels
This case study follows a 20-year old young man with ulcerative colitis and elevated AST, ALT, Alkaline Phosphatase, and IgG4, as well as narrowed bile ducts and liver inflammation and fibrosis. While steroids lowered his liver enzymes in the him short-term, they increased when he tapered off, so he was prescribed oral vancomycin (OV) at […]